Tradename | Proper Name | Approved on | Approval agency | Marketing-authorisation holder | Indication/ Therapeutic area |
---|---|---|---|---|---|
REXIN-G | Retroviral Expression Vectors Bearing Inhibitory Genes | September 2003 | U.S. Food & Drug Administration (US-FDA) | Epeius Biotechnologies | Metastatic cancers |
GENDICINE | Recombinant human p53 oncolytic adenovirus | October 2003 | China State Food & Drug Administration (CFDA) | Shenzhen SiBiono GeneTech | Head and neck cancer |
ONCORINE | Recombinant Human Adenovirus Type 5 Injection | November 2005 | China State Food & Drug Administration (CFDA) | Shanghai Sunway Biotech | Head and neck and esophagus cancer, Nasopharyngeal cancer, etc |
PROVENGE | Sipuleucel-T | April 2010 | U.S. Food & Drug Administration (US-FDA) | Dendreon Corporation | Treatment of metastatic castrate resistant (hormone refractory) prostate cancer |
IMLYGIC | Talimogene laherparepvec | December 2015 December 2021 | European Medicines Agency (EMA) U.S. Food & Drug Administration (US-FDA) | Amgen Europe B.V | Melanoma |
KYMRIAH | Tisagenlecleucel | August 2017 August 2018 | U.S. Food & Drug Administration (US-FDA) European Medicines Agency (EMA) | Novartis Pharmaceuticals Corporation | Relapsed B-cell acute lymphoblastic leukemia |
YESCARTA | Axicabtagene ciloleucel | October 2017 August 2018 | U.S. Food & Drug Administration (US-FDA) European Medicines Agency (EMA) | Kite Pharma EU B.V., NL | Relapsed or refractory large B-cell lymphoma |
TECARTUS | Brexucabtagene autoleucel | July 2020 December 2020 | U.S. Food & Drug Administration (US-FDA) European Medicines Agency (EMA) | Kite Pharma EU B.V., NL | Relapsed or refractory mantle cell lymphoma (MCL) or B-cell precursor acute lymphoblastic leukemia (ALL) |
BREYANZI | Lisocabtagene maraleucel | February 2021 | U.S. Food & Drug Administration (US-FDA) | Juno Therapeutics, Inc | Relapsed or refractory large B-cell lymphoma |
ABECMA | Idecabtagene vicleucel | March 2021 | U.S. Food & Drug Administration (US-FDA) and European Medicines Agency (EMA) | Celgene Corporation | Relapsed or refractory multiple myeloma |
CARVYKTI | Ciltacabtagene autoleucel | February 2022 | U.S. Food & Drug Administration (US-FDA) | Janssen Biotech, Inc | Relapsed or refractory multiple myeloma |
ADSTILADRIN | nadofaragene firadenovec-vncg | December 2022 | U.S. Food & Drug Administration (US-FDA) | Ferring Pharmaceuticals A/S | High-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) |